#United States #New York #Semler Scientific #Mersana Therapeutics #Cidara Therapeutics

Investigation into Major Merger Transactions

Class Action Attorney Juan Monteverde, representing Monteverde & Associates PC, is at the forefront of a critical investigation into several mergers that could significantly impact shareholders in 2026. The firm has built a reputation for recovering millions of dollars for investors, securing its position as a Top 50 Firm according to the 2024 ISS Securities Class Action Services Report. This article delves deep into the ongoing investigations concerning Semler Scientific, Mersana Therapeutics, Cidara Therapeutics, and Ryerson Holding Corporation.

Semler Scientific, Inc. (NASDAQ SMLR)

The investigation into Semler Scientific pertains to its impending sale to Strive, Inc. Semler shareholders are slated to receive 21.05 shares of Strive Class A common stock for each share of Semler they own. The shareholder vote on this transaction is set for January 13, 2026. Monteverde & Associates has urged affected shareholders to act promptly, assisting them through the evaluation of their rights and potential outcomes of the merger.

More detailed information can be accessed here. Significantly, Monteverde emphasizes that this evaluation comes at no financial obligation to the shareholders.

Mersana Therapeutics, Inc. (NASDAQ MRSN)

The next spotlight in the investigations is Mersana Therapeutics, which is undergoing a sale to Day One Biopharmaceuticals. Under the terms proposed, Mersana shareholders would receive $25.00 per share in cash, alongside a non-tradeable contingent value right (CVR) entitling them to potential milestone payments, which can elevate the total cash consideration to as high as $55.25 per share. Shareholders are urged to respond quickly as the tender offer deadline is January 5, 2026. More specifics can be found here.

Cidara Therapeutics, Inc. (NASDAQ CDTX)

Cidara Therapeutics is also in focus due to its expected sale to Merck Sharp & Dohme LLC. Current shareholders are set to receive $221.50 per share in cash. The deadline for the tender offer is January 6, 2026, prompting urgency for shareholders to evaluate how this transaction could affect their investments. The details are accessible here.

Ryerson Holding Corporation (NYSE RYI)

Lastly, attention is directed toward Ryerson Holding Corporation's merger with Olympic Steel, Inc. Upon completion of this merger, Ryerson shareholders are projected to hold a 63% stake in the combined entity. The firm has provided a channel for shareholders to seek advice on navigating the merger process and understanding their rights, with more details available here.

Why Choose Monteverde & Associates?

Monteverde & Associates PC, operating from the iconic Empire State Building in New York City, advocates fiercely for shareholders. Known for its prowess in successful litigation in national class action securities cases, the firm reassures stakeholders that no entity, be it a company or its executives, is beyond accountability under the law. Interested parties holding shares in any of the aforementioned companies are invited to reach out for a no-cost consultation regarding their options and rights. For further engagements, contact Juan Monteverde directly via email at [email protected] or call (212) 971-1341.

In conclusion, as these major mergers loom, affected shareholders must stay informed and proactive to safeguard their investments. Monteverde & Associates PC stands ready to assist those navigating these transitions, ensuring that shareholder rights are prioritized and upheld.